You just read:

Daiichi Sankyo, Inc. Announces New Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at the ACC 66th Annual Scientific Session

News provided by

Daiichi Sankyo, Inc.

Mar 13, 2017, 08:00 ET